Episode 270: 269. What is the Harm in Aspirin?

Episode 270: 269. What is the Harm in Aspirin?

The trial was terminated after 1015 patients with atrial cardiopathy had been randomized to receive either apixaban or aspirin for a mean follow-up of 1.8 years, recurrent stroke rates were identical (40 events per group; 4.4% annualized rate). There were 7 symptomatic intracranial hemorrhages in the aspirin group and none in the apixaban group, though other major hemorrhages occurred at similar rates

Aspirin is not benign and has real risk--

BTW don't give anticoagulation if the patient does not have atrial fib.

https://jamanetwork.com/journals/jama/article-abstract/2814933

Episoder(387)

Episode 264: 263. Rates of Atrial Fibrillation 12 months After Onset of Hospitalized Transient AF

Episode 264: 263. Rates of Atrial Fibrillation 12 months After Onset of Hospitalized Transient AF

patients who have new-onset transient AF detected during a hospitalization for noncardiac surgery or medical illness and are discharged in sinus rhythm, approximately 1 in 3 have AF detected in the ye...

4 Apr 20247min

Episode 263: 262. Does Omalizumab Help For Peanut Allergy?

Episode 263: 262. Does Omalizumab Help For Peanut Allergy?

Bottom line Omalizumab does seem to improve allergic reactions to peanuts but comes at a steep price tag. Likely only allergist will prescribe this drug but it is worth know about If you know or take ...

3 Apr 20248min

Episode 262: 261. Are Combined Oral Contraceptives Effective for Treating Acne?

Episode 262: 261. Are Combined Oral Contraceptives Effective for Treating Acne?

At ~24 weeks, ~80-90% of females report improvement in their acne with COCs, compared to 50-80% placebo, and 30-50% will have clear-almost clear skin versus 10-40% on placebo. Efficacy appears similar...

2 Apr 20249min

Episode 260: QM on Spring Break

Episode 260: QM on Spring Break

QM on Spring Break-- but do you like the new format? Andrewbuelt@gmail.com

20 Mar 202452s

Episode 261: 260. SGLT2 Summary Recap

Episode 261: 260. SGLT2 Summary Recap

Diabetic patient- Empagliflozin prevents death from cardiovascular causes: NNT 46 per 3.1 yrs ($600 a month, 1 million dollars per life saved)-HFpEF- SGLT2 inhibitors do not prevent death and cost rou...

19 Mar 20246min

Episode 259: 259. EMPULSE Trial- Empagliflozin and Win Ratios

Episode 259: 259. EMPULSE Trial- Empagliflozin and Win Ratios

These findings indicate that initiation of empagliflozin in patients hospitalized for acute heart failure is well tolerated and results in significant clinical benefit in the 90 days after starting tr...

18 Mar 20249min

Episode 258: 258. SOLOIST-WHF -- Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure

Episode 258: 258. SOLOIST-WHF -- Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure

Primary Outcome: Composite of deaths from cardiovascular causes or hospitalizations and urgent visits for heart failureDeath was not improved!NNT of 5 for hospitalizations and urgent visits -- However...

15 Mar 20249min

Episode 257: 256. EMPEROR-Reduced- Cardiovascular Outcomes with Empagliflozin in Heart Failure

Episode 257: 256. EMPEROR-Reduced- Cardiovascular Outcomes with Empagliflozin in Heart Failure

NNT of 20 to prevent 1 hospitalization at 16 months of follow upThey composite outcome was driven by decrease hospitalizations NOT deathhttps://www.nejm.org/doi/full/10.1056/NEJMoa2022190

14 Mar 20249min

Populært innen Helse

lydartikler-fra-aftenposten
fastlegen
hvordan-har-du-det-mann
rss-gukild-johaug
psykodrama
leger-om-livet
relasjonspodden-med-dora-thorhallsdottir-kjersti-idem
rss-garne-damer
foreldreradet
hjernesterk
rss-lopedrommen
morten-ramm-lar-kakla-ga-til-du-sovner
bak-fasaden-en-reise-i-livet-med-sykepleier-ine
g-punktet
hormonelle-frida
klimaks
rss-kull
helsetipspodden
rss-sunn-okonomi
treningsprat